AbbVie
Biotechnology
ABBV
$ 145 (0.59)%
Share price
$ 257 bn
Market Cap
$ 317 bn
Enterprise Value
Carbon footprint
2 Ton
+22%
Primary Climate Goal
-5.4%
AbbVie aims to reduce Scope 1 + 2 by 25% by 2025 from a base year 2015
This target has not been verified as science based according to SBTi
GHG emissions and Carbon intensity
AbbVie reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 625 Kt (+112/+22% y-o-y). At the sime time, carbon intensity declined marginally to 11 t (-0.1 /-0.9% y-o-y).
No public disclosure of Scope 3 emissions has been found for AbbVie at the moment.
The company is committed to reducing Scope 1 + 2 by 25% by 2025 from a base year 2015, which translates into the estimated reduction of -34 Kt per annum over the period of FY2022 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Copyright © 2023 Exerica. All rights reserved.